RPG Life Sciences Limited has expanded its board with the appointment of Dr. Pratit Samdani as an Additional Non-Executive Independent Director, effective April 29, 2026. The appointment is for a five-year term, running through April 28, 2031, and is subject to the approval of shareholders at the upcoming Annual General Meeting.
Samdani, described as one of Mumbai’s most respected physicians, brings more than two decades of experience in Internal Medicine and Critical Care. He is celebrated for his clinical expertise, academic leadership, and pioneering research in diabetes, hypertension, infectious diseases, and intensive care medicine. His credentials include a gold medal in FCPS (Medicine) and a second-rank achievement in MD (Internal Medicine) from Bombay University, alongside publications in prominent journals such as BMJ and JAMA India. He has served as Chief Investigator and Principal Investigator on numerous national and international multicentric clinical trials.
Industry observers view the appointment as a signal that RPG Life Sciences intends to fortify its governance with deep medical and scientific insight, potentially guiding strategy, risk management, and patient-centric priorities in a competitive life sciences landscape. By welcoming a physician of Samdani’s caliber, the company underscores a commitment to integrating rigorous clinical perspectives into board-level decision-making.
The company notes that Dr. Samdani is not related to any director or key managerial personnel and has affirmed that he is not debarred from holding the office of director. His appointment as an Additional Non-Executive Independent Director is intended to strengthen the board’s oversight, alongside ongoing governance updates, including a refreshed framework governing disclosure and conduct.